Therefore, we believe that rather than blocking NF-κB pathway globally, the ideal agent for the treatment of KSHV-associated lymphoproliferative disorders should selectively block K13-induced NF-κB activation. This evidence concerns the gene NFKB1 and lymphoproliferative syndrome.